Abstract
A major problem of current cancer treatments is the lack of effective therapy against metastatic disease. In many situations, primary tumors can be completely removed by surgery, or are at least partially responsive to chemotherapy and/or radiation therapy. However, residual metastatic cells at distant sites may be unresponsive to these treatments, and their subsequent growth can be lethal. In a setting of minimal residual disease, such as following primary tumor removal, or reduction of tumor mass by chemotherapy and/or radiation therapy, immunotherapy may be an effective treatment modality. One of our goals is to develop immunotherapies for the treatment of metastatic disease.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Baskar, S., L. Glimcher, N. Nabavi, R. T. Jones, and S. Ostrand-Rosenberg, 1995: Major histocompatibility complex class H+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181, 619–629.
Dexter, D., H. Kowalski, B. Blazar, Z. Fligiel, R. Vogel, and G. Heppner, 1978: Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res. 38, 3174–3181.
Aslakson, C., and F. Miller, 1992: Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52, 1399–1405.
Miller, F., B. Miller, and G. Heppner, 1983: Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 3, 22–31.
Pulaski, B., and S. Ostrand-Rosenberg, 1997: MHC class II and B7.1 immunotherapeutic cell-based vaccine reduces spontaneous mammary carcinoma metastases without affecting primary tumor growth, submitted
Hsieh, C., S. Macatonia, C. Tripp, S. Wolf, A. O’Garra, and K. Murphy, 1993: Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260, 547–549.
Lamont, A., and L. Adorini, 1996: IL-12: A key cytokine in immune regulation. Immunol. Today 17, 214–217.
Tsung, K., J. Meko, G. Peplinski, Y. Tsung, and J. Norton, 1997: IL-12 induces T helper 1-directed antitumor response. J. Immunol. 158, 3359–3365.
Ostrand-Rosenberg, S., A. Thakur, and V. Clements, 1990: Rejection of mouse sarcoma cells after transfection of MHC class II genes. J. Immunol. 144, 4068–4071.
James, R., S. Edwards, K. Hui, P. Bassett, and F. Grosveld, 1991: The effect of class II gene transfection on the tumorigenicity of the H-2K negative mouse leukemia cell line K36.16. Immunology 72, 213–218.
Chen, P., and H. Ananthaswamy, 1993: Rejection of K.1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. J. Immunol. 151, 244–255.
Armstrong, T., V. Clements, B. Martin, J. P.-Y. Ting, and S. Ostrand-Rosenberg, 1997: Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc. Natl. Acad. Sci. USA 120, 123–128.
Ostrand-Rosenberg, S., V. Clements, and L. Marr, 1986: 402AX teratocarcinoma MHC class I antigen expression is regulated in vivo by Lyt1, Lyt2, and L3T4 expressing splenic T cells. Cell. Immunol. 98, 257–265.
Ostrand-Rosenberg, S., S. Baskar, N. Patterson, and V. Clements, 1996: Expression of MHC class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells. Tissue Antigens 47, 414–421.
Bevan, M., 1976: Cross-priming for a secondary cytototxic response to minor H antigens with H-2 congenie cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143, 1283–1288.
Bevan, M., 1976: Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming. J. Immunol. 117, 2233–2238.
Lanzavecchia, A., 1996: Mechanisms of antigen uptake for presentation. Curr. Opin. Immunol. 8, 348–354.
Huang, A., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky, 1994: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961–965.
Pulaski, B., K. Yeh, N. Shastri, K. Maltby, D. Penney, E. Lord, and J. Frelinger, 1996: IL-3 enhances CTL development and class I MHC presentation of exogenous antigen by tumor-infiltrating macrophages. Proc. Natl. Acad. Sci. USA 93, 3669–3674.
Cayeux, S., G. Richter, G. Noffz, B. Dorken, and T. Blankenstein, 1997: Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation. J. Immunol. 158, 2834–2841.
Ostrand-Rosenberg, S., and A. Cohn, 1981: H-2 antigen expression on teratocarcinoma cells passaged in genetically resistant mice is regulated by lymphoid cells. Proc. Natl. Acad. Sci., USA 78, 7106–7110.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ostrand-Rosenberg, S., Pulaski, B.A., Armstrong, T.D., Clements, V.K. (1998). Immunotherapy of Established Tumor with MHC Class II and B7.1 Cell-Based Tumor Vaccines. In: Walden, P., Trefzer, U., Sterry, W., Farzaneh, F., Zambon, P. (eds) Gene Therapy of Cancer. Advances in Experimental Medicine and Biology, vol 451. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5357-1_42
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5357-1_42
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7444-2
Online ISBN: 978-1-4615-5357-1
eBook Packages: Springer Book Archive